A preprint* released yesterday by collaborators from the medical schools of Stanford, Columbia, University of Minnesota, UC San Diego, and Taiwan's China Medical School provided the first evidence of the expression of ACE2 in the upper respiratory tract among humans with different risk factors and found that it is slightly lower in those using ACE inhibitors than in controls, but no different from controls in those using angiotensin receptor blockers (ARBs).